Halxim CV Tablet is a combination antibiotic formulation containing Cefixime 200 mg and Clavulanic Acid 125 mg, designed for the treatment of a broad spectrum of bacterial infections. Cefixime, a third-generation cephalosporin, exerts bactericidal activity by inhibiting bacterial cell wall synthesis, effectively targeting both Gram-positive and Gram-negative organisms. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Cefixime by preventing the degradation of the antibiotic by beta-lactamase enzymes produced by resistant bacteria. This synergistic combination is particularly effective against infections caused by beta-lactamase-producing strains, thereby expanding the antibacterial spectrum. Halxim CV is indicated for the management of respiratory tract infections, urinary tract infections, otitis media, skin and soft tissue infections, and other susceptible bacterial infections. The tablet should be administered as prescribed by a healthcare professional, with dosage adjustments based on the severity of infection and patient-specific factors such as renal function. Common side effects may include gastrointestinal disturbances, hypersensitivity reactions, and alterations in liver function tests. Caution is advised in patients with a history of penicillin or cephalosporin allergy. Halxim CV Tablet offers a potent therapeutic option for combating resistant bacterial infections when used appropriately under medical supervision.